Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Passes Below 200 Day Moving Average – Here’s Why

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $5.03 and traded as low as $4.18. Bolt Biotherapeutics shares last traded at $4.20, with a volume of 8,958 shares changing hands.

Analyst Ratings Changes

A number of analysts have recently commented on BOLT shares. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Rodman & Renshaw began coverage on Bolt Biotherapeutics in a research report on Thursday, May 28th. They set a “buy” rating and a $22.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Monday, April 20th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Bolt Biotherapeutics presently has an average rating of “Hold” and an average price target of $34.67.

Bolt Biotherapeutics Stock Performance

The firm has a market capitalization of $8.06 million, a P/E ratio of -0.26 and a beta of 1.12. The company has a current ratio of 3.51, a quick ratio of 3.51 and a debt-to-equity ratio of 0.98. The business’s 50 day simple moving average is $4.72 and its two-hundred day simple moving average is $5.03.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative return on equity of 100.89% and a negative net margin of 455.15%.The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $1.50 million. Sell-side analysts anticipate that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Bolt Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC boosted its stake in Bolt Biotherapeutics by 19.8% during the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after purchasing an additional 2,448 shares during the last quarter. Shay Capital LLC bought a new stake in shares of Bolt Biotherapeutics in the 3rd quarter worth $85,000. Susquehanna International Group LLP bought a new stake in shares of Bolt Biotherapeutics in the 3rd quarter worth $89,000. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Bolt Biotherapeutics in the fourth quarter worth $112,000. Finally, T3 Companies LLC purchased a new position in shares of Bolt Biotherapeutics in the fourth quarter worth $208,000. 86.70% of the stock is owned by institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.